Use of NAMPT inhibitors in the preparation of drugs for preventing and / or treating pigmented villonodular synovitis
The NAMPT inhibitor FK866 inhibits the NAMPT-ITGA5-JUND signaling pathway, solves the surgical risk and recurrence problems in PVNS treatment, and realizes effective drug treatment for PVNS, significantly alleviating inflammation and tumor growth and improving clinical symptoms.
Patent Information
- Application Number
- CN202411084913.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-08-08
AI Technical Summary
Existing treatments for pigmented villous synovitis (PVNS) have surgical risks and recurrence problems, and there is a lack of effective drug treatment options.
A NAMPT inhibitor FK866 was developed to prevent and treat PVNS by inhibiting the NAMPT-ITGA5-JUND signaling pathway, blocking abnormal activation of macrophages and endothelial cells, alleviating inflammation and tumor growth.
FK866 significantly inhibits inflammation and tumor growth of PVNS, improves clinical symptoms, reduces joint destruction and hemorrhagic lesions, hinders tumor progression, and provides a potential solution for drug treatment.
Smart Images

Figure CN118593494B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medicines, and in particular relates to the use of a NAMPT inhibitor in preparing a medicine for preventing and / or treating pigmented villonodular synovitis. Background Art
[0002] Pigmented villonodullar synovitis (PVNS) is a benign intra-articular soft tissue tumor. Its pathological features are proliferation of synovial chorionic lesions, accompanied by iron yellow pigmentation and inflammatory cell infiltration, and it is locally invasive. Clinical manifestations include long-term swelling and pain in the joints, limited movement, and bloody joint fluid will be revealed by puncture. The incidence of PVNS is 4 / million, and it is more common in the knee joint. In addition, PVNS may lead to extra-articular invasion, ultimately leading to joint replacement or even amputation.
[0003] Currently, common treatments for PVNS include surgical resection, external irradiation, radiosynovectomy, and drug therapy, among which arthroscopic resection is the main treatment method. However, some patients are not suitable for surgery, and the tumor may recur even after surgery. Therefore, it is of great significance to develop drugs to treat PVNS. Summary of the invention
[0004] The object of the present invention is to provide a use of a NAMPT inhibitor in the preparation of a medicament for preventing and / or treating pigmented villonodular synovitis.
[0005] The present invention provides use of a NAMPT inhibitor in preparing a medicament for preventing and / or treating pigmented villonodular synovitis.
[0006] Furthermore, the NAMPT inhibitor is KF866.
[0007] The structure of FK866 is .
[0008] Furthermore, the drug is a drug that reduces endothelial cell damage.
[0009] Furthermore, the drug is a drug that reduces vascular permeability.
[0010] Furthermore, the drug is a drug that reduces fibrinogen deposition around blood vessels.
[0011] Furthermore, the drug is a drug for inhibiting the growth of synovial tumors.
[0012] Furthermore, the drug is a drug for alleviating synovial inflammation.
[0013] Furthermore, the drug is a preparation prepared with a NAMPT inhibitor as an active ingredient and pharmaceutically acceptable excipients.
[0014] Furthermore, the preparation is an oral preparation or an injection preparation.
[0015] Furthermore, the oral preparation is a tablet, granule, pill, capsule, suspension or emulsion.
[0016] The present invention has achieved the following beneficial effects:
[0017] PVNS tissue is composed of macrophages, endothelial cells, vascular smooth muscle cells, fibroblasts, lymphocytes, etc. A large number of immune cell infiltration and increased cytokine secretion in PVNS patients' synovial cells lead to inflammation, and increased cell proliferation and migration lead to the manifestation of tumor phenotypes. The present invention found that local osteoclastogenesis and macrophage activation increased in PVNS patients.
[0018] The present invention uses bulk RNA-seq and proteomics, scRNA-seq and spatial transcriptomics to jointly analyze and find that the NAMPT-ITGA5-JUND signaling pathway acts as a connection between macrophages and endothelial cells to regulate the progression of PVNS disease. NAMPT regulates the role and potential molecular mechanism of osteoclast-like macrophage differentiation in the pathogenesis of PVNS by promoting JUND expression. Therefore, inhibiting the MAMPT-ITGA5-JUND signaling pathway and blocking the damage of osteoclast-like macrophages to endothelial cells are of great significance in the treatment of PVNS.
[0019] The present invention finds that FK-866 can inhibit the activation of the NAMPT-ITGA5-JUND pathway of PVNS endothelial cells and macrophages, thereby inhibiting the abnormal activation of macrophages, including inhibiting endothelial cell damage, inhibiting the secretion of inflammatory factors and chemokines by endothelial cells and macrophages, thereby improving the patient's synovial inflammation and joint destruction.
[0020] Based on the PVNS-PDX mouse model, the present invention found that the NAMPT inhibitor FK866 showed significant therapeutic effects on PVNS, including improving disease-related clinical symptoms and inhibiting PVNS graft proliferation. It was found that FK866 was able to target the NAMPT-ITGA5-JUND signal transduction axis, reduce endothelial cell damage and vascular permeability, reduce synovial inflammation, reduce synovial tumor graft volume, reduce hemorrhagic lesions of PVNS and hinder tumor progression.
[0021] Therefore, NAMPT inhibitors have broad application prospects in the preparation of drugs for preventing and / or treating PVNS.
[0022] Combining the content of the present invention with the common knowledge in the art, it can be known that, in addition to FK866, other NAMPT inhibitors known in the art also have broad application prospects in the preparation of drugs for preventing and / or treating PVNS.
[0023] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0024] The above contents of the present invention are further described in detail below through specific implementation methods in the form of examples. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 The pathological process of PVNS discovered by bulk RNA-seq and proteomics. A: Schematic diagram of the overall workflow of the research plan of the present invention. B: Arthroscopic observation and MRI characteristics of PVNS.
[0026] Figure 2 The pathological process of PVNS found by bulk RNA-seq and proteomics. A: Cluster analysis heat map of differential mRNA (TOP40) expression in the Control group. B: GSEA enrichment map of representative signaling pathways upregulated mRNA in PVNS group samples compared with the Control group samples. C: KEGG enrichment analysis top10 (upregulated differential mRNA) bubble map.
[0027] Figure 3 The pathological process of PVNS discovered by bulk RNA-seq and proteomics. A: Cluster analysis heat map of differential protein (TOP40) expression in the Control group. B: GSEA enrichment map of representative signaling pathways of upregulated proteins in PVNS group samples compared with the Control group. C: KEGG enrichment analysis top10 (upregulated differential proteins) bubble map.
[0028] Figure 4The pathological process of PVNS found by bulk RNA-seq and proteomics. A: Correlation between log2(FC) of differentially expressed mRNA and log2(FC) of differentially expressed proteins ( / log FC / ≥ 1; p value < 0.05), red groups refer to upregulated mRNAs in RNA seq and upregulated proteins in proteomics. B: Bubble chart analysis of GO enrichment (TOP20) and co-elevation of mRNA and protein expression. C: Bubble chart analysis of KEGG enrichment (TOP20) mRNA and protein co-expression genes.
[0029] Figure 5 The pathological process of PVNS discovered by bulk RNA-seq and proteomics. A: Principal component analysis (PCA) uses mRNA expression to show the relationship between samples in different dimensions. B: Principal component analysis (PCA) uses protein expression to show the relationship between samples in different dimensions.
[0030] Figure 6 Figure 1. Human PVNS synovial cell atlas resolved for single-cell sequencing. A: t-SNE visualization of donor origin in Control and PVNS samples. B: t-SNE visualization of all cell clusters in the collected specimens. C: Percentage of cell clusters identified in Control and PVNS samples. D: t-SNE visualization of cell clusters at each sample level. E: Proportion of cell subsets at each sample level. F: Heat map of selected marker genes in each cell subset. G: Expression distribution feature map of selected subset-specific genes.
[0031] Figure 7 Characterization of macrophages. A: t-SNE visualization of macrophage subsets. B: t-SNE visualization of the distribution of macrophage subsets in Control and PVNS samples. C: Percentage of identified cell subsets in Control and PVNS samples. D: Bubble plot reveals the normalized expression of DEGs for each subcluster defined. E: Violin plot shows osteoclast-related genes in macrophage subsets. F: Immunohistochemical staining of ACP5, CTSK, and TNFRSF11A in Control and PVNS samples.
[0032] Figure 8Characterization of endothelial cells and endothelial cell subsets. A: t-SNE visualization of endothelial cell subsets. B: Proportions of 7 identified subpopulations in Control and PVNS groups. C: t-SNE visualization of the distribution of endothelial cells subpopulations in Control and PVNS samples. D: Percentage of identified cell subpopulations in Control and PVNS samples. E: Bubble plots reveal the normalized expression of DEGs for each subpopulation defined.
[0033] Fig. 9 To identify the key role of macrophage subsets and characterize osteoclast-like macrophages in PVNS. A: GO enrichment analysis of differentially expressed genes in macrophage subsets. B: Quantitative immunohistochemical analysis of ACP5, CTSK and TNFRSF11A. C: GO enrichment analysis of differentially expressed genes in endothelial cells subsets.
[0034] Fig.10 Figure 1. The relationship between the inferred signaling network and vascular endothelial cell injury. A: Network diagram comparing the intensity of cell interactions in the intercellular communication network between tissues. B. Heat map comparing the number of cell interactions in the intercellular communication network between tissues. C: The donut plot shows the potential cytokines and chemokines expressed in immune cells in the synovium of the PVNS and Control groups. D: The bubble plot generated by Cell Chat shows the potential ligand-receptor pairs, and there is a close relationship between Mac 6 and endothelial cells. EG: Violin plots show representative marker genes of the Visfatin signaling pathway expressed in macrophages and endothelial cells. H: Western blot showing the expression levels of NAMPT, ITGA5, and JUND in the synovium of different groups. I: SCENIC analysis of endothelial cell subsets in the Control and PVNS groups. J: Immunohistochemical staining of NAMPT, ITGA5, and JUND in Control and PVNS samples.
[0035] Fig.11Single Cell Regulatory Network Inference and Cluster Analysis (SCENIC) was used to investigate gene regulation mechanisms in PVNS endothelial cells. A: Quantitative analysis of NAMPT, ITGA5, and JUND by immunohistochemistry. B: Quantitative analysis of NAMPT, ITGA5, and JUND by western blot. C: Quantitative real-time PCR (n = 3 per group). D: Violin plot showing ITGB1 expressed in endothelial cells.
[0036] Fig.12 Results of spatial transcriptomic study of human joint synovium. A: H&E staining of synovium in PVNS group and Control group. B: Spatial heat map of ACP5, CTSK and TNFRSF11A expression in synovial samples. C: Focus map showing the spatial distribution of different cell populations in PVNS group and Control group. D: Spatial heat map of NAMPT, ITGB1 and JUND expression in synovial samples.
[0037] Fig.13 Results of in vivo experiments of NAMPT inhibitors in the treatment of PVNS. A: Schematic diagram of the treatment regimen of NAMPT inhibitors. B: H&E staining of different groups. C: Western blot showing the expression levels of JUND in the synovium of different groups. D: Results of immunohistochemical staining of JUND in samples of the PDX and FK886 groups (scale bar: 200μm). E: Evans blue (EB) concentration of PVNS grafts 14 days after FK886 or saline; since EB binds to albumin in vivo, leakage of this protein into the extravascular lumen is an indicator of vascular permeability. Values are recorded as EB: ng / mg tissue. F: Immunofluorescence staining of FGB, CD31 in the PDX and FK886 groups (scale bar: 50μm). G: Images of PVNS synovial grafts on day 16.
[0038] Fig.14 Results of in vivo experiments using NAMPT inhibitors to treat PVNS. A: In vivo gross images of tumor-bearing kidneys. B: In vitro gross images of tumor-bearing kidneys. C: Quantitative analysis of JUND protein blot. D: Quantitative analysis of JUND immunohistochemistry. DETAILED DESCRIPTION
[0039] The reagents or instruments used in the present invention without indicating the manufacturer are all conventional products that can be purchased through regular channels. The experimental methods in the examples of the present invention are all conventional methods unless otherwise specified. The test materials used in the examples of the present invention are all commercially available products unless otherwise specified.
[0040] Example 1. Genomics and proteomics study of PVNS patients
[0041] 1. Experimental Methods
[0042] (1) Sample collection
[0043] Synovial tissues were collected from 25 patients with PVNS and 15 patients with meniscus injury as controls. The synovial tissues were obtained from patients who underwent arthroscopic synovectomy. A portion of each sample was frozen in liquid nitrogen and subsequently transferred to a -80°C freezer for further analysis, while the other portion was immediately fixed in 10% neutral buffered formalin. All patients were diagnosed by intraoperative pathological examination and confirmed under arthroscopy.
[0044] (2) Bulk RNA sequencing
[0045] RNA extraction and purification: Synovial tissue (SM) samples were removed from -80°C and ground thoroughly in a homogenizer tube. Total RNA was extracted using TRIZOL reagent (catalog #15596-018, Life Technologies, Carlsbad, CA, US) according to the manufacturer's instructions, and RNA integrity was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, US) with RIN number. Qualified total RNA was further purified using the RNeasy Micro Kit (#74004, QIAGEN, Hilden, Germany) and the RNase-free DNase Set (#79254, QIAGEN, Hilden, Germany). Each slide was hybridized with 1.65 μg of Cy3-labeled cRNA using the Gene Expression Hybridization Kit (Catalog #5188-5242, Agilent Technologies, Santa Clara, CA, US) in a hybridization oven (Catalog #G2545A, Agilent Technologies, Santa Clara, CA, US) according to the manufacturer's instructions. After 17 h of hybridization, slides were washed in staining dishes (#121, Thermo Shandon, Waltham, MA, US) using the Gene Expression Wash Buffer Kit (#5188-5327, Agilent Technologies, Santa Clara, CA, US) according to the manufacturer's instructions. Data acquisition: Slides were scanned using an Agilent microarray scanner (#G2565CA, Agilent Technologies, Santa Clara, CA, US) with default settings: dye channel set to green, scanning resolution of 3 μm, photomultiplier tube (PMT) at 100%, and bit depth of 20 bits. Data were extracted using Feature Extraction software version 10.7 (Agilent Technologies, Santa Clara, CA, US). Raw data were normalized using the quantile algorithm in GeneSpring software version 11.0 (Agilent Technologies, Santa Clara, CA, US).
[0046] (3) Proteomic analysis
[0047] The SM sample was removed from -80°C and ground thoroughly in a homogenizer tube. To prevent protein degradation, 250 μl PBS and protease inhibitors (Roche, 4693132001) were added, followed by 250 μl ST buffer (2% SDS + 100 mmol / L) for protein denaturation. The tube was centrifuged at 8000 g for 1 min, and the supernatant was transferred to a new vial. After a boiling water bath and ultrasonic treatment, the supernatant was centrifuged again at 8000 g for 15 min. The resulting supernatant was collected and the protein concentration was measured using a bicinchoninic acid (BCA) kit (Thermo Fisher, 23235). Reductive alkylation was performed by adding dithiothreitol and iodoacetamide to the protein solution. The solution was then replaced with a 50 mmol / L ammonium bicarbonate solution using a FASP column (PALL, OD010C34). The processed protein solution was digested with trypsin at 37°C overnight, and then the peptides were collected and quantified using a peptide quantification kit (ThermoFisher, 23275). High-performance liquid chromatography (HPLC) conditions and mass spectrometry (MS): EASY-nLC 1200 was used with an Orbitrap Fusion Lumos Tribrid mass spectrometer system for analysis. The peptides were loaded onto a 75 μm × 15 cm C18 column packed with 1.6 μm C18 particles at a flow rate of 300 nL / min and separated using a gradient of 0.1% formic acid (solvent A) and 80% acetonitrile plus 0.1% formic acid (solvent B) for 78 minutes. The LC separation gradient was set as follows: 3-8% solvent B in 3 min, 8-22% solvent B in 44 min, 22-35% solvent B in 16 min, 35-55% solvent B in 6 min, 55-95% solvent B in 2 min, and then held at 95% solvent B for 7 min. The analytical column temperature was maintained at 55 °C using a column oven kit. The ion source settings, including spray voltage, sweep gas, and ion transfer tube temperature, were derived from the tune settings and adjusted according to the current state of the instrument. Specific parameters for the DIA-MS method included 1 MS1 scan and 40 MS2 scans with an overlap of 1 m / z between windows. For the MS1 scan, the scan range was 350–1500 m / z, the resolution at m / z 200 was 60,000, the AGC target value was set to 1.0×10^6, and the maximum injection time was 50 ms. For MS2 scans, the normalized HCD collision energy was set to 32%, the step was ±5%, the resolution was 30,000 at m / z 200, the AGC target was 5.0×10^4, and the maximum injection time was 54 ms. The same settings were used for both MS1 and MS2 scans: the RF lens was set to 40%, and spectra were collected in profile mode.
[0048] (4) Screening of differentially expressed genes
[0049] Gene Spring software was used to normalize the raw data, and then fold change (fold of expression difference) and Student's t test were used as statistical methods to screen differentially expressed genes. The selection criteria were as follows: 1. fold change (linear) <= 2 or fold change (linear) >= 2; 2. T test p value < 0.05.
[0050] (5) Processing of single-cell RNA-seq data
[0051] Sequencing data were aligned to the human reference genome GRCh38 using CellRanger count version 4.0.0 to obtain gene expression matrices at the single-cell level. Subsequently, the gene expression matrix was imported into a Seurat object for further downstream analysis (version 4.3.0). To ensure the quality of cells used in subsequent analysis, a rigorous quality control (QC) pipeline was implemented. Specifically, for each sample, DoubletFinder was used to predict droplets that might encapsulate multiple cells, and only cells predicted to be “Singlet” were retained. Cells that exhibited a high proportion of mitochondrial gene expression (>10%) and a high proportion of transcripts mapped to dissociation-induced genes (>10%) were filtered out, referring to previous studies. In addition, cells with unique molecular identifier (UMI) counts (<500), gene counts (<200), and log10GenesPerUMI values less than 0.8 were also excluded.
[0052] (6) Single-cell RNA-seq data analysis
[0053] After filtering, the present invention obtained 52341 cells for subsequent analysis. SCTransform normalization was applied, and then PCA dimensionality reduction was performed using the top 3000 variable genes except mitochondrial, ribosome and hemoglobin genes. Harmony was used to eliminate batch effects. FindNeighbors selected the first 9 PCs to calculate the KNN nearest distance, followed by FindClusters for unsupervised clustering. Nonlinear dimensionality reduction t-SNE or UMAP was performed for single-cell data visualization, and consistent with unsupervised clustering, a resolution of 0.7 was selected for both clustering and nonlinear dimensionality reduction. In order to identify specific cell types, the FindAllMarkers function was applied to pinpoint marker genes from clusters from unsupervised clustering. In order to further investigate the degeneration process of synovial cells by immune cells, specific cell subsets were extracted for more in-depth analysis. This involved repeating the SCTransform normalization, dimensionality reduction, batch effect removal, clustering, and marker gene identification steps.
[0054] (7) Differential gene expression analysis
[0055] Differential gene expression analysis was performed using the FindAllMarkers or FindMarkers functions in Seurat to compare differential gene expression between control individuals and PVNS patients and cell type subcluster markers. Default criteria included log-transformed fold change values greater than 0.25, corrected P values less than 0.05, and gene expression in more than 10% of cells. These analyses were performed using MAST, which employs a dedicated hurdle model tailored for scRNA-seq data unless otherwise stated.
[0056] (8) Analysis of transcription factor regulators
[0057] To predict potential transcriptional regulatory networks in FSPC, the present invention performed SCENIC analysis using pySCENIC. The input matrix of FSPC was a normalized expression matrix obtained from Seurat. The AUCell module of pySCENIC was used to evaluate the activity of regulators in AUC units with default thresholds. The Wilcoxon rank sum test in the FindAllMarkers function of Seurat was used to identify differential expression of regulators.
[0058] (9) Analysis of cell-cell interactions
[0059] Cell Chat (v1.6.1) was used to infer cell-cell interactions based on the expression of known ligand-receptor pairs in different cell types. The present invention followed the official tutorial to identify potential cell-cell communication networks between macrophages and endothelial cells in PVNS. Specifically, the present invention loaded the normalized counts of the relevant cell groups into CellChat and applied preprocessing functions including identifying overexpressed genes, identifying overexpression interactions, and project data using standard parameter settings. In the preliminary analysis, the core function computeCommunProb was used with the parameter set overall. size = TRUE, assuming that abundant cell populations tend to collectively transmit stronger signals than rare cell populations. In addition, standard parameters were also applied to compute CommunProb Pathway and aggregateNet. Finally, to identify significant signal changes between Control and PVNS, the present invention used a variety of comparison and visualization functions in Cell Chat, such as compare interactions, netVisual_heatmap, and ranking similarity.
[0060] (10) Functional analysis
[0061] The present invention performed gene set enrichment analysis including GO enrichment and GSEA in Reactome using the clusterProfiler package (version 3.18.1).
[0062] (11) Processing of spatial transcriptomics data
[0063] Raw sequencing reads from spatial transcriptomics were quality checked and mapped to a pre-built human reference genome GRCh38 using Space Ranger v2.0.1 and default settings. The gene spot matrix from Space Ranger was imported into a Seurat object for further quality control and analysis using the Seurat software package (version 4.3.0). The present invention filtered spots based on at least 200 gene detections and a minimum of 500 UMI counts, while removing genes expressed by less than 10 spots. In addition, spots with more than 10% mitochondrial counts or more than 20% ribosome counts were excluded.
[0064] (12) Spatial transcriptomics data analysis
[0065] We applied SCTransform normalization on the filtered points and clustered them at a resolution of 0.6 using the first 11 principal components (PCs) from principal component analysis (PCA). Cells were visualized on the same dimensions used in clustering using the Uniform Manifold Approximation and Projection (UMAP) algorithm. Spatial feature expression plots were generated using the SpatialFeaturePlot and VlnPlot functions in Seurat (version 4.3.0). To assign cell types to synovial samples in spatial transcriptomics, we employed robust cell type decomposition (RCTD) in full mode. This approach allows for the assignment of multiple cell types at each point and is particularly recommended for platforms such as 10xGenomics Visium. The vizAllTopics function in STdeconvolve (version 1.6.0) was used to visualize the proportional weight of each cell type within a single point.
[0066] (13) iTALK analysis
[0067] The present invention also uses the iTALK package to reveal the intercellular regulation of cytokine and chemokine levels in normal and disease groups, respectively. The present invention inputs the raw count matrix of Mac6 and Ec2. Only the top 100 regulatory effects are selected and displayed. If the ligand is derived from a cytokine, the present invention marks this regulatory effect with a red line and marks other regulatory effects with a black line.
[0068] 2. Experimental results
[0069] (1) Patients and clinical samples
[0070] The present invention used synovial tissue samples obtained from four patients diagnosed with PVNS and four matched adjacent normal tissues for comprehensive analysis, including large amounts of RNA-seq data, proteomics data, and spatial transcriptomics analysis, as well as scRNA-seq. The present invention selected 25 patients diagnosed with PVNS of the knee and 15 patients with meniscus injuries of the knee as the source of synovial samples, and named them as the PVNS group (P) and the Control group (C), respectively. The present invention used arthroscopy and MRI to carefully examine the general characteristics of the PVNS group. Arthroscopic images vividly depict the synovial tissue of patients in the PVNS group, showing a unique reddish-brown hue attributed to hemosiderin deposition, with a distinct proliferative morphology compared with the Control group ( Figure 1 B). Meanwhile, MRI scans showed high signal of synovial tissue in fs-pd sequence. It is noteworthy that patients with PVNS showed significant joint swelling and cartilage erosion within the knee joint ( Figure 1B).
[0071] (2) Pathological processes revealed by bulk RNA-seq and proteomics.
[0072] The principal component analysis (PCA) visualization showed that samples from the same group tended to cluster together, indicating a more compact spatial arrangement, while samples from different groups showed a greater degree of dispersion ( Figure 5 A, B). Bulk RNA-seq analysis revealed a total of 1785 differentially expressed mRNA genes, including 994 upregulated genes and 791 downregulated genes. The heat map of the top 40 differentially expressed genes provided further clarification, revealing that the expression of genes related to inflammation and injury was enhanced in the PVNS group compared with the Control group (Figure 2A). Subsequent gene ontology (GO) and gene set enrichment analysis (GSEA) of differentially expressed genes (DEGs) revealed enrichment in processes related to immune factors and immune system regulation (Figure 2B,. In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis pointed out that osteoclast differentiation was a significantly affected pathway in PVNS (Figure 2C). In the proteomic analysis, the heat map of the top 40 differentially expressed proteins showed that the expression of proteins related to inflammation and injury was increased in the PVNS group compared with the Control group (Figure 3A). GO and GSEA enrichment analysis of DEGs indicated that they are involved in the adaptive immune response and the regulation of immune response ( Figure 3 B). Further analysis of KEGG enrichment of differentially expressed proteins revealed pathways such as antigen processing and presentation and osteoclast differentiation ( Figure 3 C). Joint analysis of differentially expressed mRNAs and proteins revealed distinct patterns, with a particular emphasis on the 164 upregulated genes and proteins in the third quadrant ( Figure 4 A). GO enrichment analysis of these genes highlighted functions related to immune response and immune system regulation ( Figure 4 B), while KEGG enrichment analysis showed osteoclast differentiation ( Fig.14 C). Overall, the differentially expressed genes and proteins identified by bulk RNA-seq and proteomic analyses were enriched in processes related to immune regulation, monocyte differentiation, and osteoclast differentiation, providing valuable insights into the pathogenesis of PVNS.
[0073] (3) Single-cell sequencing analysis of the human knee PVNS cell map
[0074] To further investigate the differentiation mechanisms of monocytes and osteoclasts, we performed single-cell RNA sequencing analysis. Overall, we identified five distinct cell populations. Initially, unsupervised t-distributed stochastic neighbor embedding (t-SNE) was used to depict the cellular composition of all samples (Figure 6A). Subsequently, we identified five major cell types, namely macrophages, fibroblasts, endothelial cells, vascular smooth muscle cells, and T cells (Figure 6A). Figure 6 B, C), differentiated by specific marker genes ( Figure 6 F). Specifically, macrophages were described by the marker genes C1QA and TYROBP, endothelial cells were described by VWF and EMCN, smooth muscle cells were described by TAGLN and ACTA2, fibroblasts were described by COL1A1 and LUM, and T cells were described by CD2, CD3D, NKG7, and GNLY (Figure 6G). It is worth noting that different distributions of cells from different specimens were observed on the t-SNE maps, which were particularly evident in macrophages, with significant differences between the Control group and the PVNS group ( Figure 6 D). Subsequently, the present invention carefully examined the cell composition of each sample. Compared with the control group, the increase in macrophages was the most significant, becoming the main cell type in the PVNS group. In contrast, the vascular endothelial cells associated with blood vessels decreased in the PVNS group. In addition, a decrease in the number of vascular smooth muscle cells was also observed in the PVNS group ( Figure 6 E).
[0075] (4) Identification of the key role of macrophage subsets and characterization of osteoclast-like macrophages in PVNS
[0076] Leveraging insights gained from bulk RNA-seq and proteomic analyses on monocyte and osteoclast differentiation, we performed a comprehensive cluster analysis of macrophage populations across all samples, revealing nine distinct macrophage subsets ( Figure 7A). The nine subpopulations were named Mac1, Mac2, Mac3, Mac4, Mac5, Mac6, Mac7, Mac8, and Mac9. Visualization of macrophage clusters on t-SNE plots revealed different distributions, with different proportions of each subpopulation observed in different sample groups. Notably, all macrophage subpopulations in the PVNS group showed higher proportions compared to the Control group, with Mac6 and Mac7 showing the most obvious differences ( Figure 7 To characterize these macrophage subsets, we performed DEG analysis in these nine clusters ( Figure 7 D). Subsequently, by integrating the observed changes in cell cluster proportions and differential gene expression, the present invention depicted the different functional characteristics of each macrophage subset through GO enrichment analysis ( Fig. 9 A): Mac1 was identified as a basal macrophage subset, showing responses to chemokines and chemotactic cells (C1QC, CD14); Mac2 was associated with GO terms related to muscle contraction and muscular system processes, defining a subset of chemotactic motile cells (CALD1, TAGLN); Mac3 was characterized by responses to tumor necrosis factor, representing a precursor subset of macrophage differentiation (S100A9, S100A9); Mac4 was linked to chemoattractant-mediated signaling pathways, indicating a subset of cells related to immune chemoattractant functions (ACKR1, SPARCL1); Mac5, which was enriched in GO terms related to antigen processing and exogenous antigen presentation, depicted an antigen presentation-related subpopulation (CD1C, HLA-DQB1); Mac6 showed GO terms related to the regulation of intrinsic apoptotic signaling pathways, defining it as an invasion-related subpopulation (H2AFZ, STMN1); Mac7 showed GO terms related to bone remodeling, indicating a functional subpopulation involved in matrix remodeling; Mac8 was characterized by GO terms related to prostaglandin metabolic processes terms, defining a subset with inflammatory regulatory functions (TPSB2, TPSAB1). Finally, Mac9 exhibited GO terms related to blood coagulation, defining it as a subset of tissue repair functions involved in wound healing (TFF3, TFPI). Comparative analysis of differentially expressed genes between the Mac6 and Mac7 groups (Figure 7E) showed upregulation of osteoclast-related genes, including ACP5, CTSK, and TNFRSF11A. Subsequent examination of the gene expression profiles of Mac6 and Mac7 cells between groups indicated that these subpopulations were primarily responsible for the pathological damage and tissue destruction of PVNS, thus determining the name of the osteoclast-like macrophage cluster. Immunohistochemistry (IHC) analysis further confirmed the presence of osteoclast-like macrophages in PVNS tissue ( Figure 7 F, Fig. 9B). Due to the increased vascular permeability and subsequent blood leakage associated with this condition, there is a significant accumulation of erythrocytes in the synovial fluid. Cluster analysis of endothelial cell subsets identified seven distinct endothelial cell subsets ( Figure 8 Compared with the Control group, except for Ec5, the proportions of all six cell subsets in the PVNS group were reduced ( Figure 8 B). In addition, there were significant differences in the proportion of endothelial cell subclusters in each sample between the PVNS and Control groups ( Figure 8 C, D). The differentially expressed genes in these seven subgroups were analyzed in depth ( Figure 8 E), and further supplemented with GO enrichment analysis of these genes ( Fig. 9 C). The GO terms of the Ec1 group described it as a subpopulation of basal endothelial cells involved in the cellular response to nutrients (POSTN, HES1). The Ec2 group was characterized as a damage-induced subpopulation of endothelial cells (RGCC, CXCL12), with GO terms including cadherin and negative regulation of cell-cell adhesion mediated by endothelial development. Meanwhile, the Ec3 group was described as an immune chemotaxis-related subpopulation (ACKR1, CCL23) with GO terms such as monocyte chemotaxis and chemokine-mediated signaling pathway. On the other hand, the Ec4 group represented a lipid-binding endothelial cell subpopulation associated with GO terms such as lipid transport and fatty acid transport (FABP4, CD36). The Ec5 group was identified as an immune response subpopulation involved in antigen processing and presentation of exogenous peptide antigens (APOE, TYROBP). In addition, the Ec6 group was defined as a vascular extracellular matrix-related subpopulation (DCN, COL1A2), with GO terms including collagen fiber organization and extracellular matrix organization. GO terms attributed to the Ec7 group included “muscle system process” and “assembly of cellular components involved in morphogenesis,” defining it as an epithelial-mesenchymal transition subgroup (RGS5, ACTA2). The present invention hypothesized that the Ec2 group would be significantly associated with endothelial cell injury.
[0077] (5) The inferred signaling network is related to vascular endothelial cell damage
[0078] To elucidate the interactions between macrophages and endothelial cell subsets in the PVNS microenvironment and to clarify the underlying mechanisms of PVNS-related inflammation and infiltration injury, the present invention employed CellChat analysis. Fig.10 A) shows that the PVNS group exhibited stronger cell-to-cell interaction intensity compared with the Control group. Enhanced crosstalk was mainly observed between Mac6 and Ec2, Ec4, Ec7 and other major cell clusters. The heat map of the interaction number of the present invention further shows that ( Fig.10B), Mac6 subpopulation showed the most significant increase in communication with other cell subsets in the PVNS group compared with the Control group.
[0079] Clinical observations showed that PVNS patients had a large amount of blood infiltration and red blood cell leakage in the joints, indicating that vascular endothelial cells in the affected area may be damaged, which is closely related to disease progression. The representative ligand-receptor interaction loop diagram also showed that the interaction of cytokines and chemokines, such as CCL2, CCL3, CCL4, CCL5, and CCL3L1, was significantly increased in the PVNS group compared with the normal group ( Fig.10 D). It can be inferred that the inflammatory level of PVNS is significantly higher than that of normal specimens, which promotes the damage of macrophages to endothelial cells. These findings indicate that the inflammatory level of PVNS tissue is significantly increased compared with the Control sample, which promotes the progression of joint hemorrhagic lesions. The signal pathway relationship bubble diagram of the present invention ( Fig.10 C, E, F) depicts that in the PVNS group, NAMPT expressed by Mac6 substantially activated ITGA5 / ITGB1 receptors on Ec2 and Ec7. This ligand-receptor pair is a component of the Visfatin signaling pathway, which is primarily involved in inflammation and immune responses and serves as a therapeutic target for inflammatory diseases. The effects of NAMPT on endothelial cells lead to endothelial cell injury and vascular structural destruction, thereby accelerating disease progression and exacerbating clinical symptoms.
[0080] Subsequently, the present invention performed single cell regulatory network inference and clustering analysis (SCENIC) to further study the gene regulatory mechanism in PVNS endothelial cells. It is worth noting that the PVNS group showed higher JUND levels ( Fig.10 G, I). Previous studies have shown that NAMPT indirectly activates JUND, leading to articular cartilage damage. The present invention further verified the protein expression levels of NAMPT, ITGA5, and JUND in the two groups, which confirmed the scRNA-seq findings of the present invention ( Fig.10 H, J and Fig.11 A, B). It is worth noting that there was no significant difference in ITGB1 expression between the two groups ( Fig.11 D). The mRNA expression analysis also showed that the protein expression results of NAMPT, ITGA5 and JUND were consistent with those of the present invention ( Fig.11 C). In conclusion, the present findings suggest that macrophages regulate the expression of the transcription factor JUND in endothelial cells via the Visfatin signaling pathway, thereby exacerbating endothelial cell injury. This mechanism may contribute to the inflammatory environment and vascular damage observed in PVNS, highlighting a potential target for therapeutic intervention.
[0081] (6) Spatial transcriptomics of human synovium in joints
[0082] To gain a more comprehensive understanding of the molecular mechanisms driving PVNS disease progression, we performed spatial transcriptome sequencing on samples from the PVNS and Control groups. Hematoxylin and eosin (H&E) staining revealed disorganized cell arrangement and fibrotic areas in the lesion tissue of the PVNS group, distinguishing it from the Control group ( Fig.12 A). Subsequently, the present invention confirmed the presence of osteoclast-like macrophages in the spatial transcriptomics (ST) data by examining the expression of ACP5, CTSK, and TNFRSF11A. Notably, the expression levels of these osteoclast-like macrophage marker genes were significantly increased in the PVNS group compared with the Control group ( Fig.12 B). In addition, using deconvolution analysis, we spatially mapped the scRNA-seq data of macrophages and endothelial cells onto the transcriptomics data. In the PVNS group, we observed a more complex cellular composition with increased abundance of Mac6 cells compared to the Control group. In addition, significant overlap in the spatial distribution of endothelial cells and Mac6 was noted within the PVNS group ( Fig.12 C), further supporting the concept of cell-cell interactions between these specific subpopulations. Analysis of gene expression within the NAMPT-ITGA5-JUND signaling pathway in both ST samples showed that NAMPT, ITGA5, and JUND were significantly upregulated in the PVNS group relative to the Control group ( Fig.12 D). Therefore, the scRNA-seq findings of the present invention were confirmed and extended by spatial transcriptomics.
[0083] Example 2: In vivo experiment on the treatment of PVNS with NAMPT inhibitor
[0084] 1. Experimental Methods
[0085] (1) Establishment of PVNS-PDX tumor model and drug administration regimen
[0086] PVNS-human tissue xenograft (PDX) tumor model was established using 5- to 6-week-old female NOD-SCID gnotobiotic mice. Human tissue source: Tumor tissue from patients with a clear diagnosis of PVNS surgery, active synovial tissue was collected during surgery and then transplanted to establish the PVNS-PDX tumor model. Mice were purchased from Weitong Lihua Co., Ltd. (Beijing, China) and housed in microisolator cages under specific pathogen-free conditions. Tumor grafts were prepared using sterile SmartFlow (Airtech, China). After resection of necrotic tissue, the tumor tissue was rinsed three times with saline. The tumor mass was then cut into small segments (1.0 to 3.0 mm in diameter) using a surgical blade. The tumor tissue (graft) was suspended in serum-free Dulbecco's modified Eagle's medium and then cryopreserved for implantation. The surgery was performed using an anesthesia machine. The mice were anesthetized with 2.5% isoflurane and placed in the lateral recumbent position. The skin was aseptically prepared with surgical grade povidone-iodine and a small dorsal midline incision (approximately 20.0 mm) was made in the area of the kidney. Once the kidney was exposed, a total volume of 25.0 mm 3 The tumor graft is gently placed under the renal capsule ( Fig.14 A). The prepared PVNS grafts were implanted within 4 hours, and the incision was closed after implantation. Drug administration and treatment Initially, the drug NAMPT inhibitor (FK866, HY-50876, MedChemExpress) was dissolved in 0.5% methylcellulose. Subsequently, the above PDX mice were randomly assigned to the PDX group (i.e., model group) and the FK866 group (i.e., treatment group) on the third day (n=3). The PDX group did not receive FK866, but was given an equal volume of saline solution; the FK866 group was designated as the treatment group and received the drug at a dose of 30 mg / kg body weight, twice a day for four consecutive days, and the dosing regimen was repeated weekly for a total of two weeks; the administration method was intraperitoneal injection. The mice were euthanized on the 16th day after administration. The tumor-bearing kidneys were carefully separated and collected for evaluation. The tumor size was measured under a microscope and calculated using the formula V = 1 / 2 (L + W), where L is the length and W is the width. The schematic diagram of the treatment regimen is shown in Fig.13 As shown in A.
[0087] (2) Immunohistochemistry
[0088] Synovial tissues were fixed in 10% neutral buffered formalin for two days and then dehydrated through a series of graded ethanol. The specimens were then embedded in paraffin and cut into 6 μm thick sections. For immunohistochemistry (IHC) analysis: Paraffin sections were incubated with 3% hydrogen peroxide 2 for 15 minutes to quench endogenous peroxidase activity and then incubated in 10% normal goat serum for 1 hour at room temperature to block nonspecific antigens. Subsequently, the sections were incubated with anti-ACP5 antibodies (1:100; ABclonal, A2528), CTSK (1:500; ABclonal, A1782), TNFRSF11A (1:100; ABclonal, A13382), NAMPT (1:100, ABclonal, A0256), ITGA5 (1:100, ABclonal, A19069), and JUND (1:1000, ABclonal, A5496). Incubated overnight at 4°C. The next day, the sections were incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies and counterstained with hematoxylin (Beyotime, C0107). All stained sections were scanned into digital images using a slide scanner for further analysis. The integrated optical density values of positive staining were evaluated using ImageJ software.
[0089] (3) Immunofluorescence
[0090] Tissue cryosections were thawed at room temperature for 1 hour, and 10-micron-thick sections were rinsed with PBS and then incubated for 2 hours with a blocking solution consisting of 5% serum, 2% bovine serum albumin, and 0.3% Triton X-100 in phosphate-buffered saline. Slides were then incubated with primary antibodies overnight at 4°C, rinsed with PBS, and incubated with secondary antibodies for 2 hours before mounting with DAPI. Tissue sections were observed using a fluorescence microscope, and fluorescence intensity was assessed using ImageJ. The primary antibodies used were: FGB (1:100; ABclonal, A1401), CD31 (1:100; ABclonal, A4900).
[0091] (4) Western blotting
[0092] Synovial tissue lysates were prepared using RIPA buffer supplemented with PMSF, incubated on ice, and physically sheared for 25 min. Proteins were extracted and their concentrations were determined using a BCA protein assay kit (Beyotime, P0011). Equal amounts of protein (40 μg) were separated on 8%-15% SDS-PAGE gels, transferred to polyvinylidene fluoride (PVDF) membranes, and incubated with appropriate primary antibodies overnight. The PVDF membranes were then washed with TBST and incubated with secondary antibodies (1:10,000; ABclonal) for 90 min at room temperature. Immunoblots were developed using BeyoECL Plus (Beyotime), and protein bands were visualized and captured using a Tanon 2500R gel imaging system (Tanon, Shanghai, China). Band intensities were quantified using ImageJ software version 1.39V. The primary antibodies used were: anti-NAMPT (1:1000, ABclonal, A0256); anti-ITGA5 (1:1000, ABclonal, A19069); anti-JUND (1:1000, ABclonal, A5496); anti-β-actin (1:1000, ABclonal, AC006).
[0093] (5) Hematoxylin-eosin staining
[0094] Paraffin sections were soaked in water for 5 min, then stained with hematoxylin solution (Solarbio, Beijing, China) for 5 min, rinsed with three changes of distilled water, differentiated in a mixture of ammonia and acid water for 30 s, and then soaked in distilled water for 15 min. Subsequently, they were stained with eosin (Solarbio, Beijing, China) for 2 min, rinsed again with distilled water three times, dehydrated through a series of graded ethanol, and cleared with xylene. Finally, the sections were mounted with neutral balsam. The tissue cavity and cell counts of each group were observed using a microscope.
[0095] qRT-PCR
[0096] (6) Total RNA was extracted from synovial tissue using the Trizol method and the RNA concentration was determined
[0097] HiScript III RT SuperMix for qPCR (Vazyme) was used to reverse transcribe total RNA into cDNA. cDNA was synthesized from 5 μg of total RNA using reagents from Promega, and then quantitative real-time PCR (qRT-PCR) was performed using SYBR Green. cDNA samples were amplified under the following conditions: 95°C for 3 min, followed by 95°C for 15 s and 60°C for 15 s for a total of 40 cycles. The target gene expression levels of the treatment and PDX groups were normalized and compared using the (1 + e)ΔΔCT method. Primer sequences were obtained from China Biotechnology Co., Ltd. The primers used in the study are listed in Table 1.
[0098] Table 1. Primer sequences used in qRT-PCR
[0099]
[0100] (7) Vascular permeability measurement
[0101] Vascular permeability of mice was measured using Evans Blue after 16 days of treatment. Evans Blue at a dose of 20 mg / kg (dissolved in heparinized phosphate-buffered saline [100 U / ml]) was injected into the tail artery of anesthetized mice. Two hours later, the transplanted tumors in the renal capsule were excised, weighed, and then placed in 2 ml of formamide. The samples were incubated at 50°C for 24 hours to extract Evans Blue. The concentration of Evans Blue in the tissue extracts was measured using a microplate reader at a wavelength of 630 nm and a standard curve of Evans Blue concentration. Thereafter, the concentrations were normalized and expressed in ng / mg.
[0102] (8) Data analysis
[0103] Data are presented as mean ± SEM. Statistical significance was determined using t-test or one-way ANOVA followed by Tukey post hoc test for multiple comparisons as performed in GraphPad Prism 5 (San Diego, USA). A p-value of less than 0.05 was set as the threshold for statistical significance. Univariate statistical analysis was performed using Wilcoxon rank sum test and fold change (FC) to evaluate the quantitative changes in metabolomics profiles. Results were visualized on a volcano plot indicating fold difference ≥ 1.5 with p-value < 0.05. P-values were adjusted to account for multiple hypothesis testing. For confident protein analysis, missing values in the data matrix were imputed to half of the minimum observed value and then normalized using the quantile function in the R package “preprocessingCore” after log2 transformation. Multivariate statistical analysis, including PCA, was performed to observe and evaluate the overall distribution pattern of all samples.
[0104] 2. Experimental results
[0105] The present invention established a PVNS-PDX mouse model by renal capsule transplantation ( Fig.14 A). Ten days after model establishment, observations showed successful implantation with significant graft vascularization ( Fig.14 B). H&E staining confirmed the preservation of the original tumor morphology within the graft ( Fig.13 B). This proves that the modeling was successful.
[0106] Compared with the PDX group, WB analysis showed that JUND expression was significantly decreased after FK866 intervention ( Fig.13 C, Fig.14 C). Similarly, IHC staining showed that JUND expression was significantly decreased in the FK866-treated group compared with the PDX group ( Fig.13 D, Fig.14 D). To evaluate vascular leakage, Evan's blue dye was intravenously injected into the PDX group 14 days later. Subsequent analysis showed that the concentration of Evan's blue dye was significantly reduced in the FK866 group compared with the PDX group (4.040±1.618 vs. 14.93±2.003 ng Evan's blue / mg tissue, p<0.001) ( Fig.13 E). Immunofluorescence examination showed that there was a large amount of fibrinogen (FGB) leakage around the blood vessels in the PDX group, accompanied by loosely arranged endothelial cells (CD31), and FGB accumulated in the interstitial spaces of endothelial cells. In contrast, the FK866 group had significantly less FGB deposition around the blood vessels and densely arranged endothelial cells ( Fig.13 F). Notably, FK866 treatment for 14 days significantly inhibited tumor growth, which may be due to the inhibition of NAMPT expression in macrophages. Fig.13 As shown in G, the final tumor size clearly demonstrates the significant anti-tumor efficacy of FK866. Overall, FK866 treatment showed significant effectiveness, including improvement of disease-related clinical symptoms and inhibition of PVNS graft proliferation. The present invention discovered the effectiveness of FK866 in targeting the NAMPT-ITGA5-JUND signaling axis, demonstrating that FK866 can reduce endothelial cell damage and vascular permeability in the PVNS-PDX mouse model, reduce synovial tumor graft volume, reduce hemorrhagic lesions of PVNS and hinder tumor progression.
[0107] The above experimental results indicate that NAMPT inhibitors have broad application prospects in the preparation of drugs for the treatment of PVNS.
Claims
1. Use of a NAMPT inhibitor in the preparation of a medicament for preventing and / or treating pigmented villonodular synovitis, wherein the NAMPT inhibitor is FK866.
2. The use according to claim 1, characterized in that The drug is a preparation prepared by taking the NAMPT inhibitor as the active ingredient and adding pharmaceutically acceptable excipients.
3. The use according to claim 2, characterized in that: The preparation is an oral preparation or an injection preparation.
4. The use according to claim 3, characterized in that The oral preparation is tablet, granule, pill, capsule, suspension or emulsion.
